| OTTAWA, ONTARIO--(Marketwire - Dec. 21, 2011) - , 2011 - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") today announced that the in-life protocol for its definitive in vivo efficacy study has been completed in accordance with the test design. In this test, a total of 168 mice were employed, with the final group euthanized on December 16 th . The investigators will now turn to collection, measurement, compilation and analysis of results, which are expected to become a...continued GAP:CA PHRGF Drugs Healthcare |
Wednesday, December 21, 2011
PharmaGap Completes In Vivo Study Protocol in Ovarian Cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment